| 영문 | interferon | 한글 | 인터페론 |
|---|---|---|---|
| 설명 | 바이러스에 감염된 동물의 세포에서 생산되는 항바이러스성 단백질. 바이러스에 감염된 조직이 생산하는 항바이러스 작용이나 항종양작용 등 생리활성이 있는 당단백질을 말한다. 1957년 영국 국립의학연구소의 A.아이작스와 J.린든먼에 의해 알려졌다. 이들은 열처리한 바이러스를 달걀 내막의 세포에 처리하고 하루 동안 배양한 다음, 배양액을 추출하여 새로운 달걀 내막과 섞은 후, 살아 있는 바이러스를 집어넣은 결과, 바이러스의 분열이 억제되었고, 그 배양액을 넣지 않은 경우에는 바이러스가 분열되어 번식하였다. 이 실험의 의미는 바이러스가 동물세포에 침입하면 방어의 기능으로 그 동물세포는 인터페론을 생산하여 바이러스의 분열을 막는다는 것이다. 제일 많이 연구된 분야는 인간의 인터페론이다. 인터페론은 바이러스감염 및 내독소 투여, 나아가서는 항원자극 등에 반응하여 갖가지 세포로부터 방출된다. IFN이라고 약기. 현재, 3종(IFN-α, IFN-β, IFN-γ)이 알려져 있으며 각각 의약품으로 사용되고 있다. |
||
| 영문 | alpha particles | 한글 | 알파입자 |
|---|---|---|---|
| 설명 | 원자에 정상보다 과다, 과소한 중성자나 양자를 가지고 있는 경우에 원자가 안정되기 위해서 붕괴가 생긴다. 이런 붕괴에는 다음과 같은 3가지 방법이 있다. 알파－붕괴는 알파입자를 방출하여 안정되는 법, 즉 원자번호는 2씩 감소하고 질량수는 4씩 감소한다. 알파입자란 알파붕괴에 의해서 생기는 헬륨의 핵과 같은 입자를 말한다. |
||
| 영문 | alpha-fetoprotein | 한글 | 알파태아단백 |
|---|---|---|---|
| 설명 | 태아의 간조직이나 소화기관에서 만들어지는 단백질. 태아기나 임산부에서 정상적으로 존재한다. 그러나 간암세포나 생식세포에 관련된 종양에서도 만들어져 이런 질병이 존재할 때에는 임산부나 태아가 아니더라도 조직이나 혈액에 나타나게 된다. 임상적으로는 간암이나 생식세포 종양의 발견과 치료효과 판정에 이용되고, 또 임신 16~18주에 산모의 혈액에서 이단백질의 양을 측정하여 태아의 비정상적인 발달을 발견할 수 있다. |
||
| IFLrA | recombinant human leukocyte interferon A |
|---|---|
| rIFN | recombinant interferon |
| IFNA | interferon alpha |
| alpha-GLUC | alpha-glucosidase |
| AOA | American Osteopathic Association; Administration on Aging; Alpha Omega Alpha Honor Society; American... |
| rIFN-alpha | Recombinant interferon alpha |
|---|---|
| rIFN-alpha-2b | Recombinant interferon-alpha-2b |
| rIFN-alpha 2a | recombinant interferon alpha 2a |
| reaferon | recombinant alpha 2-interferon |
| IFN alpha | Alpha interferon |
| alpha interferon | <cytokine> Interferon which is released by leukocytes in response to a viral infection. A protein cytokine that is used as an anticancer agent. (15 Nov 1997) |
|---|---|
| interferon-alpha | <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products. It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia. A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents. See: interferon-alpha 2a, interferon-alpha 2b Synonym: leukocyte interferon. Pharmacological action: antineoplastic agent, antiviral agent. (20 Sep 2002) |
| interferon-alpha 2a | <cytokine> Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. Pharmacological action: antineoplastic agent, antiviral agents. Chemical name: Interferon-alphaA (human leukocyte protein moiety reduced) (12 Dec 1998) |
| interferon-alpha 2b | <chemical> Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. Pharmacological action: antineoplastic agent, antiviral agents. (12 Dec 1998) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| beta interferon | A protein liberated by fibroblasts in response to a viral infection. (27 Sep 1997) |
| receptors, interferon | Specific molecular sites or structures on or in cells with which interferons react or to which they bind in order to modify the function of the cells. Interferons exert their pleiotropic effects through two different receptors. Alpha- and beta-interferon crossreact with common receptors, while gamma-interferon initiates its biological effects through its own specific receptor system. (12 Dec 1998) |
| recombinant | <molecular biology> A cell or an individual with a new combination of genes not found together in either parent, usually applied to linked genes. (18 Nov 1997) |
| recombinant clone | <molecular biology> Clones containing recombinant DNA molecules. See: recombinant DNA technologies. (14 Oct 1997) |
| recombinant clones | Clones containing recombinant DNA molecules. (12 Dec 1998) |
| recombinant DNA | <molecular biology> Spliced DNA formed from two or more different sources that have been cleaved by restriction enzymes and joined by ligases. (18 Nov 1997) |
| recombinant DNA molecules | A combination of DNA molecules of different origin that are joined using recombinant DNA technology. (12 Dec 1998) |
| recombinant DNA technologies | Procedures used to join together DNA segments in a cell-free system (an environment outside a cell ororganism). Under appropriate conditions, a recombinant DNA molecule canenter a cell and replicate there, either autonomously or after it hasbecome integrated into a cellular chromosome. (09 Oct 1997) |
| recombinant DNA technology | A series of procedures used to join together (recombine) DNA segments. A recombinant DNA molecule is constructed (recombined) from segments from 2 or more different DNA molecules. Under certain conditions, a recombinant DNA molecule can enter a cell and replicate there, autonomously (on its own) or after it has become integrated into a chromosome. (12 Dec 1998) |
| recombinant fusion proteins | Proteins that are the result of genetic engineering. A regulatory part or promoter of one or more genes is combined with a structural gene. The fusion protein is formed after transcription and translation of the fused gene. This type of fusion protein is used in the study of gene regulation or structure-activity relationships. They might also be used clinically as targeted toxins (immunotoxins). (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
알파페론연고(유전자재조합알파인터페론) - 새창
|
씨제이 |
Recombinant interferon alpha | 일반의약품 | 비급여 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|